Polymarket weighs IPO against native token launch amid $20B valuation talks

Polymarket founder Coplan teases token plan amid crypto's equity pivot

A Polymarket token would give the platform a self-funding user-acquisition tool that costs no cash upfront. That matters because competitors are already spending real money on celebrities: Kalshi has athlete partnerships, and Novig traded equity for Sydney Sweeney's endorsement. Traders who earn or stake a native token become locked into Polymarket's liquidity rather than shopping across venues.

The catch is regulatory exposure. Any distribution to U.S. users would draw SEC scrutiny and complicate Polymarket's position while state attorneys general probe its safeguards. Polymarket must choose between limiting the asset to non-U.S. pools or shaping it as a narrow utility token that survives dual-agency review.

Vanderbilt law professor says Supreme Court will weigh prediction markets

A Supreme Court review would settle the federal-state power split that is already costing platforms millions in parallel defense. Kalshi lost preemption in Ohio and Tennessee under gambling-framing theories. Polymarket faces an open New York suit. A high court ruling would replace that patchwork with one national standard.

Operators could stop funding fifty-state legal teams. The NFL has urged the court to let states regulate event contracts as gambling. The CFTC's competing swap-rule bid remains in White House review, slower than courtroom clocks. The side the Supreme Court backs will shape whether prediction markets trade as regulated futures or as state-licensed gambling products.

Kalshi asks full Sixth Circuit to rehear sports contract ruling

A full-court reversal would restore Kalshi's CFTC preemption cover in Ohio and Tennessee and slow the template other state attorneys general are already copying. A denial hardens the state-gambling framing and invites parallel suits across the Midwest and South.

Kalshi must now fund three-front legal spend: this federal appeal, state court defense elsewhere, and possible product redesign if the CFTC's swaps label lands. The CFTC's proposed rule change offers a separate federal path, but rulemaking moves in months while courts act in weeks. Either outcome sets the compliance bar every competitor races to clear.

The en banc bid extends a pattern of lost preemption shields that already includes Coinbase's Michigan retreat and Kalshi's separate Ninth Circuit fight, showing state gambling-framing victories are becoming template law faster than federal rulemaking can respond.

Kalshi drug trial prediction markets expose gaps in pharmaceutical vendor contracts

Kalshi's FDA and clinical-trial markets create direct financial exposure for drug developers that existing vendor contracts never anticipated. Companies now face scenarios where contractors, clinical research organizations, or even employees could trade against trial outcomes they influence. The contract gap means pharmaceutical firms lack clear recourse to prevent or punish such trading.

Regulators may soon demand explicit trading prohibitions in research agreements, adding compliance overhead to every vendor negotiation. The first company burned by an insider trade will likely sue its contractor for the contractual silence. That precedent would force the entire industry to rewrite standard research and service agreements. Kalshi benefits from novel contract volume while drug makers absorb the legal uncertainty.